» Articles » PMID: 36974332

Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings

Overview
Specialty Pharmacology
Date 2023 Mar 28
PMID 36974332
Authors
Affiliations
Soon will be listed here.
Abstract

Tapentadol is an analgesic compound that acts centrally to attenuate pain. Previous studies have shown that tapentadol has dual mechanisms of action as a mu-opioid receptor agonist and noradrenaline re-uptake inhibition. Therefore, tapentadol provides a great advantage over classic opioids in pain management from nociceptive to neuropathic. Cumulative evidence from in vitro data suggests that tapentadol effect of norepinephrine re-uptake could be a new target that overcomes other classic opioids in chronic neuropathic pain. Compared to tramadol and other opioids, tapentadol is associated with fewer adverse effects than tramadol. Tapentadol is a new alternative to treat acute, chronic, and neuropathic pain. Thus, this review article was focused on understanding the studies that led to the development of tapentadol as a novel analgesic drug and its advantages over conventional opioids. Thus, tapentadol is a good alternative with fewer adverse effects and is available for human use.

Citing Articles

Tapentadol: A Comprehensive Review of Its Role in Pain Management.

Zavaleta-Monestel E, Anchia-Alfaro A, Villalobos-Madriz J, Munich A, Garcia-Montero J, Quesada-Villasenor R Cureus. 2024; 16(11):e74307.

PMID: 39717323 PMC: 11666300. DOI: 10.7759/cureus.74307.


Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.

Giorgi V, Sarzi-Puttini P, Pellegrino G, Sirotti S, Atzeni F, Alciati A Curr Pain Headache Rep. 2024; 28(12):1349-1363.

PMID: 39042299 PMC: 11666752. DOI: 10.1007/s11916-024-01277-9.


Unraveling the Hippocampal Molecular and Cellular Alterations behind Tramadol and Tapentadol Neurobehavioral Toxicity.

Soares-Cardoso C, Leal S, Sa S, Dantas-Barros R, Dinis-Oliveira R, Faria J Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931463 PMC: 11206790. DOI: 10.3390/ph17060796.


Update on Musculoskeletal Pain Management.

Tsai A, Kobayashi R, Liu I, Fim M, Liggieri A, Machado E Rev Bras Ortop (Sao Paulo). 2024; 59(2):e160-e171.

PMID: 38606122 PMC: 11006528. DOI: 10.1055/s-0043-1776135.


Diabetic Neuropathic Pain: Directions for Exploring Treatments.

Chen Y, Song X Biomedicines. 2024; 12(3).

PMID: 38540203 PMC: 10967923. DOI: 10.3390/biomedicines12030589.


References
1.
Vosburg S, Severtson S, Dart R, Cicero T, Kurtz S, Parrino M . Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. J Pain. 2017; 19(4):439-453. DOI: 10.1016/j.jpain.2017.11.007. View

2.
HENDERSHOT L, FORSAITH J . Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics. J Pharmacol Exp Ther. 1959; 125(3):237-40. View

3.
Delgado P . Serotonin noradrenaline reuptake inhibitors: New hope for the treatment of chronic pain. Int J Psychiatry Clin Pract. 2014; 10 Suppl 2:16-21. DOI: 10.1080/13651500600637098. View

4.
Bujalska-Zadrozny M, Wolinska R, Lesniak A, Sacharczuk M . Central antinociceptive effect of tapentadol is increased by nitric oxide synthase inhibitors. Behav Pharmacol. 2016; 27(7):606-14. DOI: 10.1097/FBP.0000000000000255. View

5.
Malberg J, Schechter L . Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des. 2005; 11(2):145-55. DOI: 10.2174/1381612053382223. View